Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-7018 in Relapsed or Refractory NHL or CLL
NCT05515406Phase 1Terminated
- Sponsor
- Ono Pharmaceutical
- Start
- Feb 2023
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ONO-7018 in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) (2 arms), sponsored by Ono Pharmaceutical. Primary endpoints: Maximum Tolerated Dose up to 3 weeks and Treatment-Emergent Adverse Events and Treatment-Emergent Serious Adverse Events. Started Feb 2023; status: terminated.
02
Drugs
ONO-7018
03
Conditions
non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT05515406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05515406.